Pediatric Anesthesiologists Risk Halothane-Related Liver Injury

June 25, 1998

Some anesthesiologists may be accidentally inhaling too much of the potent anesthetic gas halothane when they tend to their patients, possibly putting themselves at high risk for liver injury, according to a study by researchers at Johns Hopkins and the National Institutes of Health.

The investigators found that 23 percent of pediatric anesthesiologists and 9 percent of general anesthesiologists showed higher than normal levels of antibodies to p-58, a liver protein generally found in people with hepatitis caused by exposure to halothane. The antibody level in the doctors was similar to that of one in five patients tested who had halothane hepatitis. However, none of the anesthesiologists showed signs of outright liver disease.

"It's still too early to tell whether the antibodies mean the anesthesiologists will get liver disease, or if the antibodies may be protecting them," says Dolores B. Njoku, M.D., lead author of the study and an instructor of anesthesiology and critical care medicine at Hopkins. "But there are safety precautions that anesthesiologists should take, such as making sure their masks fit tightly and not leaving the gas on during operating room preparation."

Results of the study were presented at a recent meeting of the Society for Pediatric Anesthesia in Phoenix. Researchers collected blood samples from 53 general anesthesiologists, 13 pediatric anesthesiologists, 21 patients who had developed hepatitis as a result of exposure to halothane, and 21 patients who had no exposure to anesthetic gases. They then measured autoantibodies to p-58 and P4502EI, another protein linked to halothane hepatitis.

When testing for P4502E1, the researchers found that 8 percent of the pediatric anesthesiologists, 4 percent of the general anesthesiologists and 62 percent of the halothane hepatitis patients had significant levels of antibodies.

"The findings of this study indicate that some anesthesiologists are sensitized to the same liver proteins that have been associated with halothane hepatitis," Njoku says. "It remains to be determined why these individuals have not developed liver injury."

The study's other authors were Robert S. Greenberg, M.D., and Jackie Lee Martin Jr., M.D., of Hopkins; and Mohammed Bourdi, Ph.D., and Lance Pohl, Pharm.D., Ph.D., of the National Heart, Lung and Blood Institute.

--JHMI--


Johns Hopkins Medical Institutions' news releases are available on a PRE-EMBARGOED basis on EurekAlert at http://www.eurekalert.org, Newswise at http://www.newswise.com and from the Office of Communications and Public Affairs' direct e-mail news release service. To enroll, call 410-955-4288 or send e-mail to bsimpkin@welchlink.welch.jhu.edu.

On a POST-EMBARGOED basis find them at http://hopkins.med.jhu.edu, Quadnet at http://www.quad-net.com and ScienceDaily at http://www.sciencedaily.com.
-end-


Johns Hopkins Medicine

Related Antibodies Articles from Brightsurf:

Scientist develops new way to test for COVID-19 antibodies
New research details how a cell-free test rapidly detects COVID-19 neutralizing antibodies and could aid in vaccine testing and drug discovery efforts.

Mussels connect antibodies to treat cancer
POSTECH research team develops innovative local anticancer immunotherapy technology using mussel protein.

For an effective COVID vaccine, look beyond antibodies to T-cells
Most vaccine developers are aiming solely for a robust antibody response against the SARS-CoV-2 virus, despite evidence that antibodies are not the body's primary protective response to infection by coronaviruses, says Marc Hellerstein of UC Berkeley.

Children can have COVID-19 antibodies and virus in their system simultaneously
With many questions remaining around how children spread COVID-19, Children's National Hospital researchers set out to improve the understanding of how long it takes pediatric patients with the virus to clear it from their systems, and at what point they start to make antibodies that work against the coronavirus.

The behavior of therapeutic antibodies in immunotherapy
Since the late 1990s, immunotherapy has been the frontline treatment against lymphomas where synthetic antibodies are used to stop the proliferation of cancerous white blood cells.

Re-engineering antibodies for COVID-19
Catholic University of America researcher uses 'in silico' analysis to fast-track passive immunity

Seroprevalence of antibodies to SARS-CoV-2 in 10 US sites
This study estimates how common SARS-CoV-2 antibodies are in convenience samples from 10 geographic sites in the United States.

Neutralizing antibodies in the battle against COVID-19
An important line of defense against SARS-CoV-2 is the formation of neutralizing antibodies.

Three new studies identify neutralizing antibodies against SARS-CoV-2
A trio of papers describes several newly discovered human antibodies that target the SARS-CoV-2 virus, isolated from survivors of SARS-CoV-2 and SARS-CoV infection.

More effective human antibodies possible with chicken cells
Antibodies for potential use as medicines can be made rapidly in chicken cells grown in laboratories.

Read More: Antibodies News and Antibodies Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.